Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Payables (2022 - 2025)

Historic Payables for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $1.1 million.

  • Phathom Pharmaceuticals' Payables fell 8492.92% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 8492.92%. This contributed to the annual value of $10.5 million for FY2024, which is 1661.77% down from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Payables stood at $1.1 million, which was down 8492.92% from $4.0 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Payables registered a high of $12.6 million during Q4 2023, and its lowest value of $1.1 million during Q3 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' median Payables value was $7.1 million (recorded in 2024), while the average stood at $6.9 million.
  • Its Payables has fluctuated over the past 5 years, first soared by 8342.12% in 2024, then plummeted by 8492.92% in 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' Payables (Quarter) stood at $10.0 million in 2022, then increased by 26.05% to $12.6 million in 2023, then fell by 16.62% to $10.5 million in 2024, then plummeted by 89.77% to $1.1 million in 2025.
  • Its Payables stands at $1.1 million for Q3 2025, versus $4.0 million for Q2 2025 and $11.6 million for Q1 2025.